UK-based scientists at the Institute of Cancer Research (ICR) have created a map of all 1,578 licensed drugs and their mechanisms of action to identify ‘uncharted waters’ in the search for future treatments.

Licensed through the Food and Drug Administration (FDA), the analysis of drugs found that 667 separate proteins in the human body have had drugs developed against them, which represents an estimated 3.5% of the 20,000 human proteins.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

So far, as many as 70% of all targeted drugs have been created and operate by acting on just four families of proteins.

The study analyses existing drug treatments across all diseases.

The new map reveals areas where human genes and the proteins they encode could be promising targets for new treatments. It can be used to identify other proteins with similar properties to the most heavily drugged families.

ICR data science head Dr Bissan Al-Lazikani said: “Our new study provides a comprehensive map of the current state of medicines for human disease.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"Our new study provides a comprehensive map of the current state of medicines for human disease."

“It identifies areas where drug discovery has been a spectacular success, others where there are major gaps in our armoury of medicines, and opportunities for the future in the form of promising targets and potential drug combinations.”

Scientists said that the new data could be used to improve treatments for all human aliments as diverse as cancer, mental illness, chronic pain and infectious disease.

They obtained information from the canSAR database at ICR, the ChEMBL database from the European Bioinformatics Institute (EMBL-EBI) in Cambridge and the University of New Mexico’s DrugCentral database.

By matching each drug with prescribing information and data from published scientific papers, the scientists built up a picture of how existing medicines work.

Subsequently they discovered that there are 667 unique human proteins targeted by existing approved drugs, and identified a further 189 drug targets in organisms that are dangerous to humans.

The researchers used complex ‘big data’ analytical techniques to identify four very frequently ‘drugged’ families of proteins accounting for 43% of all drug targets, and acting as targets for 70% of all approved small-molecular drugs.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact